Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7876 - 7900 of 8873 in total
TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.
Investigational
Matched Description: … TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157] …
Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.
Investigational
Matched Description: … Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers …
MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.
Investigational
Matched Description: … MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins. …
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
Matched Description: … BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis …
ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
Investigational
Matched Description: … ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing …
RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).
Investigational
Matched Description: … RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase …
PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.
Investigational
Matched Description: … PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme …
Peresolimab is under investigation in clinical trial NCT04634253 (A Study of LY3462817 in Participants With Rheumatoid Arthritis).
Investigational
Matched Description: … Peresolimab is under investigation in clinical trial NCT04634253 (A Study of LY3462817 in Participants …
Ponsegromab is under investigation in clinical trial NCT05492500 (A Study of Ponsegromab in People With Heart Failure).
Investigational
Matched Description: … Ponsegromab is under investigation in clinical trial NCT05492500 (A Study of Ponsegromab in People With …
Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).
Investigational
Matched Description: … Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug …
Lexacalcitol is a solid. This compound belongs to the vitamin D and derivatives class of chemicals. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. It is known to target the vitamin D3 receptor.
Experimental
Matched Description: … This compound belongs to the vitamin D and derivatives class of chemicals. …
Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
Investigational
Matched Description: … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. …
ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
Investigational
Matched Description: … oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of
Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).
Investigational
Matched Description: … under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of
Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).
Investigational
Matched Description: … NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of
Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
Investigational
Matched Description: … Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination …
AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. …
Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a hydroxyquinoline derivative unrelated to other classes of drugs. Nitroxoline is active against bacterial gyrases.
Experimental
Matched Description: … It is a hydroxyquinoline derivative unrelated to other classes of drugs. …
Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.
Experimental
Matched Description: … It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties …
Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement. It displays high oral bioavailability and water solubiltiy compared to other magnesium salts such as magnesium citrate, magnesium carbonate and magnesium oxide.
Experimental
Matched Description: … Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement …
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute …
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly …
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
Matched Description: … Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of
Displaying drugs 7876 - 7900 of 8873 in total